ReviewFrontiers in endocrinology2026
Pediatric hyperuricemia: genetic basis, metabolic mechanisms, and clinical implications.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia (HUA) is a heterogeneous group of metabolic disorders caused by long-term disturbances in purine metabolism. In recent years, although adult HUA and gout have been extensively studied, the understanding of HUA and gout in children and adolescents remains insufficient. Diagnostic criteria for adult HUA are well-established, but no consensus has yet been reached regarding its definition in children and adolescents. This review summarizes the current understanding of pediatric HUA, emphasizing its genetic basis, metabolic mechanisms, and clinical associations. ATP-binding cassette subfamily G member 2 (ABCG2) dysfunction, gene-defined forms of autosomal dominant tubulointerstitial kidney disease (ADTKD), particularly ADTKD-UMOD and ADTKD-REN, and selected purine metabolism disorders contribute to early-onset HUA, gout, nephrolithiasis, and renal involvement. Obesity-related insulin resistance (IR) may promote urate accumulation through pathways linked to oxidative stress, endothelial dysfunction, and inflammasome activation. Persistent elevation of uric acid (UA) has been associated with chronic kidney disease (CKD) progression, elevated blood pressure (BP), and subclinical cardiovascular remodeling. However, many of these mechanistic associations are supported primarily by adult and experimental studies and require further validation in children. We also review non-pharmacological management and indication-based pharmacological treatment strategies for pediatric HUA. These indications include asymptomatic hyperuricemia (AH), pediatric gout, UA nephrolithiasis, inherited purine metabolism disorders, CKD-associated HUA, and tumor lysis syndrome (TLS)-associated acute HUA, with emphasis on pediatric evidence, regulatory approval, off-label use, dosing, monitoring, and safety. In children, asymptomatic serum urate elevation is often the first recognized presentation, whereas nephrolithiasis, gout, renal dysfunction, or acute HUA should prompt evaluation for genetic, metabolic, renal, or treatment-related causes. These findings underscore the need for early identification and personalized intervention in children with HUA to prevent long-term renal and metabolic complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.